Abstract:Abstract Glioblastoma (GBM) is the most malignant primary tumor in the central nervous system of adults. Temozolomide (TMZ), an alkylating agent, is the first-line chemotherapeutic agent for GBM patients. However, its efficacy is often limited by innate or acquired chemoresistance. Cancer cells can rewire their metabolic programming to support rapid growth and sustain cell survival against chemotherapies. An example is the de novo serine synthesis pathway (SSP), one of the main branches from glycolysis that is highly activated in multiple cancers in promoting cancer progression and inducing chemotherapy resistance. However, the roles of SSP in TMZ therapy for GBM patients remain unexplored. In this study, we employed NCT503, a highly selective inhibitor of phosphoglycerate dehydrogenase (PHGDH, the first rate-limiting enzyme of SSP), to study whether inhibition of SSP may enhance TMZ efficacy in MGMT-positive GBMs. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), flowcytometry and colony formation assays demonstrated that NCT503 worked synergistically with TMZ in suppressing GBM cell growth and inducing apoptosis in T98G and U118 cells in vitro. U118 and patient-derived GBM subcutaneous xenograft models showed that combined NCT503 and TMZ treatment inhibited GBM growth and promoted apoptosis more significantly than would each treatment alone in vivo. Mechanistically, we found that NCT503 treatment decreased MGMT expression possibly by modulating the Wnt/β-catenin pathway. Moreover, intracellular levels of reactive oxygen species were elevated especially when NCT503 and TMZ treatments were combined, and the synergistic effects could be partially negated by NAC, a classic scavenger of reactive oxygen species. Taken together, these results suggest that NCT503 may be a promising agent for augmenting TMZ efficacy in the treatment of GBM, especially in TMZ-resistant GBMs with high expression of MGMT. Pharmacological inhibition of the serine synthesis pathway with a highly selective inhibitor NCT503 synergistically works with temozolomide in inhibiting O6-methylguanine DNA methyltransferase (MGMT)-positive glioblastoma cell growth and inducing apoptosis both in vitro and in vivo. Mechanistically, NCT503 treatment reduces MGMT expression possibly via Wnt/βcatenin pathway. Reactive oxygen species-mediated DNA damage is at least partially involved. Combinational administration of NCT503 and TMZ may represent a novel and promising treatment strategy to enhance TMZ efficacy in patients with MGMT-high glioblastoma.

Experimental Study of Selective MGMT Peptides Mimicking TMZ Drug Resistance in Glioma.

O-6-Methylguanine-Dna Methyltransferase (Mgmt): Challenges And New Opportunities In Glioma Chemotherapy

A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co‐Delivery of Temozolomide and a Methylguanine‐DNA Methyltransferase Inhibitor

Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

O6-methylguanine DNA Methyltransferase As a Promising Target for the Treatment of Temozolomide-Resistant Gliomas

MGMT Expression and Temozolomide Resistance in Glioma Stem-like Cells

Enhanced MGMT Expression Contributes to Temozolomide Resistance in Glioma Stem-Like Cells

20(S)‐ginsenoside‐rg3 Reverses Temozolomide Resistance and Restrains Epithelial‐mesenchymal Transition Progression in Glioblastoma

Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81

Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

[Individualized Chemotherapy Based on Drug Sensitivity and Resistance Assay and MGMT Protein Expression for Patients with Malignant Glioma--analysis of 42 Cases].

Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide

Effect of Interferon-Α/β on Temozolomide Activity Against MGMT-positive Glioma Stem-Like Cells in Vitro and in Vivo.

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

IFN-α/β Enhance Temozolomide Cytotoxic Activity Against Human Glioma in vivo

Temozolomide Chemotherapy Based on MGMT Protein Expression for Patients with Malignant Gliomas:A Report of 40 Cases

Personalized Chemotherapy Based on O6-methylguanine-DNA methyltransferase (MGMT) Expression Pattern for Glioma Patients

Potent Predictive CpG Signature for Temozolomide Response in Non-Glioma-cpg Island Methylator Phenotype Glioblastomas with Methylated MGMT Promoter.